July 5, 2020

WuXi PharmaTech Cayman : and PRA Health Sciences Restructure Relationship in China

0
0



Pin It

Screen Shot 2016-01-07 at 10.57.06 AMSHANGHAI, and RALEIGH, N.C., 2015-12-08 01:00 CET (GLOBE NEWSWIRE) —
WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading open-access R&D capability
and technology platform company serving the pharmaceutical, biotechnology, and
medical device industries, and Health Sciences, Inc. (NASDAQ:PRAH), a
leading global clinical contract research organization, today announced a
restructuring of their relationship for the delivery of clinical trial
management services in China, Macau and . The two companies formed a
joint venture for this purpose in March 2013.

Under the new arrangement, the portion of the joint venture located in mainland
China will become a wholly owned subsidiary of WuXi, and the portion of the
joint venture located in Hong Kong will become a wholly owned subsidiary of
PRA. In addition, PRA will retain its business in China and
Hong Kong, which offers custom-built clinical development solutions to
sponsors. In connection with this restructuring, PRA and WuXi will form a
preferred provider relationship under which WuXi will provide full-service
clinical trial services for global clinical trials subcontracted by PRA in
China.

“WuXi approached us to explore the restructuring of our relationship to better
align with their current objectives in China,” said PRA’s CEO Colin Shannon.
“This restructuring allows us to continue our strong relationship with WuXi to
support our client needs in China and to leverage the business that we have
built together.”

“We appreciate PRA’s strong support for the WuXiPRA joint venture over the past
three years,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “Even with
this change in the structure of our relationship, WuXi and PRA will remain
strong business partners in China.”

ABOUT WUXI PHARMA TECH

WuXi PharmaTech is a leading open-access R&D capability and technology platform
company serving the pharmaceutical, biotechnology, and medical device
industries, with operations in China and the United States. As a
research-driven and customer-focused company, WuXi PharmaTech provides a broad
and integrated portfolio of services throughout the drug and medical device R&D
process. WuXi is also building a platform to provide clinical diagnostic
services directly to physicians and their patients globally. WuXi PharmaTech’s
services are designed to assist its global partners in shortening the cycle and
lowering the cost of drug and medical device R&D. WuXi PharmaTech’s operating
subsidiaries are known as WuXi AppTec. For more information, please visit
http://www.wuxiapptec.com.

ABOUT PRA HEALTH SCIENCES

At PRA Health Sciences, providing innovative solutions for our clients is what
we do. Side-by-side with our clients, we strive to move drug discovery forward,
helping them to develop life-saving and life-improving drugs. PRA has more than
11,000 employees working in 80+ countries providing comprehensive clinical
development services across all phases. From full service clinical development
to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of
solutions that meet the demands of a diverse marketplace. PRA has worked on
100+ marketed drugs across several therapeutic areas and conducted the pivotal
or supportive trials that led to FDA and/or international regulatory approval
of 50+ such drugs.

For more information, please contact:

WuXi PharmaTech

Investors
Ronald Aldridge
LaVoieHealthScience
+1 617-374-8800 x109
+1 617-792-2459
[email protected]

Media
Aaron Shi
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
[email protected]

PRA Health Sciences

Investors
Linda Baddour
Chief Financial Officer
Mike Bonello
Corporate Controller
+1 919-786-8270
[email protected]

Media
Christine Rogers
Manager—Public Relations
+1 919-786-8463
[email protected]

Copyright © 2015 OMX AB (publ).
Copyright © 2015 OMX AB (publ), source OMX

Print Friendly, PDF & Email
About ieyenews

Speak Your Mind

*